As of Saturday, 22 August 2026, we have successfully completed the synthesis and an initial pilot batch of our own research product. We are presenting the project here without disclosing its final name, complete structure or data sheet. This information will be published only after the independent characterisation has been completed.
As part of the development work carried out to date, several batches comprising a total of approximately 50 to 100 grams of the material have already been produced. This demonstrates that the selected route is generally feasible beyond a small-scale proof-of-concept experiment. However, it does not yet establish conclusively confirmed identity and purity, reproducible batch-to-batch consistency or a validated manufacturing process.
A representative sample will shortly be analysed by an independent laboratory. We currently expect independent analysis, specification development, process optimisation and the establishment of reproducible manufacturing to take approximately six months. The material will not be available to order until then.
Initial pilot batch
The fundamental synthesis route has been implemented successfully. At the current development scale, a total of approximately 50 to 100 grams of the target material has already been produced. The project has therefore progressed beyond the milligram-scale or basic feasibility stage.
Independent confirmation of the chemical identity, purity according to the final specification, reproducibility between individual batches and transfer to a controlled manufacturing process are nevertheless still outstanding. Potential by-products and batch-dependent variations must also be investigated systematically.
The existing quantity constitutes a research and pilot batch. It has not been approved for sale. The material will not be listed until independent analysis, the specification and documented batch release have been completed.
Analysis, process optimisation and timeline
The independent laboratory will initially examine the identity and purity of a representative sample. We currently do not have our own robust receptor-binding or functional data. Chemical and analytical characterisation and the assessment of batch consistency therefore take priority.
At the current development scale, the calculated manufacturing costs are approximately €500/g. Through optimisation of the route, more efficient work-up and larger reproducible batches, we aim to achieve a target of approximately €100/g. This does not constitute a binding sales price.
We currently expect it to take approximately six months before the material could potentially be listed as reference material. This period includes independent analysis, possible refinement of the synthesis route, process optimisation, repeat and comparison batches, specification development and preparation of the data sheet. There is no binding publication date.
Legal classification in Germany
Status as of the date of this article: Saturday, 22 August 2026. This reflects our interpretation of the legislation currently in force and does not constitute legal advice or a decision by any competent authority. NpSG status is not equivalent to general marketability. Statutory lists and case law may change.
BtMG
This substance is not explicitly listed by name in Schedules I, II or III of the German Narcotics Act (BtMG). Most recent amendment to the schedules: 27th BtMG Schedules Amendment Ordinance, Federal Law Gazette 2026 I No. 150, effective from 23 May 2026.
The opioid-related core structures covered there—morphinans, 4-phenylpiperidines/prodine-type substances, pethidine analogues, fentanyls and benzimidazoles/nitazenes—do not correspond to this 2-(arylalkyl)piperidine scaffold. The absence of a current listing does not rule out the possibility of the substance being added in the future.
NpSG
The German New Psychoactive Substances Act (NpSG) operates through substance groups listed in Schedule 1 and individual substances listed in Schedule 2. The current framework is based on the Sixth Ordinance of 26 November 2025 and the Amending Act of 7 January 2026, including amendments to Schedule 2.
Schedule 2, which covers 1,4-butanediol, GBL and nitrous oxide, is not relevant here. Schedule 1 covers, among other groups, 2-phenethylamines with an Ar–C–C–N core, cannabimimetics, benzodiazepines, N-(2-aminocyclohexyl)amides, tryptamines/ergolenes, arylcyclohexylamines, benzimidazoles, 3,3-diphenylpropan-1-amines and 4-amino-1-benzylpiperidines.
In this scaffold, the arylalkyl chain is attached to the ring carbon adjacent to the nitrogen atom. Its connectivity is Ar–C–C–C–N rather than the phenethylamine chain Ar–C–C–N. The opioid-related groups 7 to 9 require different core structures: benzimidazole, diphenylpropylamine or 4-amino-1-benzylpiperidine. According to this interpretation, the substance does not currently fall under Schedule 1 or Schedule 2. This is not a judicial determination.
The fact that a substance is not covered by the BtMG or NpSG does not mean that it may be marketed without restriction. Food law, chemicals legislation and other regulatory requirements may also apply. Please also refer to our update on the NpSG and marketability.
Sources
- BtMG: consolidated version
- BtMG Schedule I, Schedule II, Schedule III
- 27th BtMG Schedules Amendment Ordinance: Federal Law Gazette 2026 I No. 150
- NpSG: consolidated version
- NpSG Schedule 1, Schedule 2
- Sixth NpSG Schedules Ordinance: Federal Law Gazette 2025 I No. 292
- Act Amending the NpSG: Federal Law Gazette 2026 I No. 2
- Section 2 AMG: definition of a medicinal product
Status: 22 August 2026. General information only; not legal advice. Legislation, administrative practice and case law may change.
For research purposes only
Exclusively for scientific, analytical and laboratory research. Not intended for use in or on humans or animals.
Your Remicals.de Team